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NRP- 1 monoclonal antibody in combination with metronomic chemotherapy
(MCT) inhibits the growth of gastric cancer xenografts in nude mice
DING Yuan1, XU Yun1, CHEN Yuqiang1, YAN Jianghua2（1. Department of Oncology, No. 174 Hospital of PLA,
Chenggong Hospital Affiliated to Xiamen University, Xiamen 361003, Fujian, China; 2. Cancer Research Center,
Medical College of Xiamen University, Xiamen 361005, Fujian, China)
[Abstract] Objective: To investigate the antitumor effect of NRP-1 monoclonal antibody combined with docetaxel
metronomic chemotherapy in nude mice bearing gastric cancer xenografts. Methods: BALB / c mice were inoculat-
ed subcutaneously with BGC-823 cells to establish xenograft model; the tumor bearing rats were randomly divided
into control group, NRP-1 monoclonal antibody group (NRP-1mAb), rhythm chemotherapy group (MCT) and com-
bined group (NRP-1mAb+MCT). Except the control group, the other three groups were given the corresponding
treatment on the 8th day after the model establishment. After 2 weeks of administration, the general condition of
nude mice was observed and the body weight and tumor volume were measured the next day. The mice were sacri-
ficed and the mass of tumor was calculated; HE staining was used to observe the morphology of the tumor tissue.
The expression of NRP-1 protein, VEGF and MVD were detected by immunohistochemistry. Results: The tumor
volume (0.613±0.223 vs 0.866±0.115, 1.098±0.343, 1.474±0.644 V/cm3; P<0.05) and weight (0.394±0.128 vs 0.748±
0.152, 0.867±0.361, 1.247±0.494 m/g; P<0.05) of the combined group were significantly lower than those of the
other groups, and the tumor inhibition rate was statistically higher compared with the other treatment groups (P<
0.05). Under microscope, the cancer cells in the control group were well grown and the blood vessels were rich; the
cancerous tissues of each treatment group showed different degree of sheet necrosis and the blood vessel composi-
tion decreased. Immunohistochemistry results showed that the expression of NRP-1 in the control group was signifi-
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cantly higher than that in each treatment group (P<0.05); and the expression of NRP-1, VEGF and MVD in com-
bined treatment group was significantly lower than the other groups. Conclusion: NRP-1 monoclonal antibody com-
bined with docetaxel rhythmic chemotherapy may significantly inhibit the growth and angiogenesis of BGC- 823
gastric cancer by down-regulating the expression of NRP-1.
[Key words] gastric cancer; transplanted tumor in nude mice; NRP-1 mAb; metronomic chemotherapy(MCT)；vascular
endothelial growth factor（VEGF）




































































加入一抗（NRP-1抗体 1∶100稀释），置于 37 ℃恒温
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Tab.1 NRP-1 monoclonal antibody in combined with
metronomic chemotherapy (MCT) reduced the volume and





































A:Ctr group; B:NRP-1mAb group; C: MCT group; D: NRP-1mAb+MCT group
图1 NRP-1单抗联合节律化疗抑制裸鼠胃癌移植瘤生长(H-E, ×400)
Fig.1 NRP-1 monoclonal antibody in combined with metronomic chemotherapy (MCT)












A:Ctrl group; B:NRP-1mAb group; C: MCT group; D:NRP-1mAb+MCT group
图2 NRP-1mAb与MCT联合治疗后移植瘤组织中NRP-1表达水平下降（×400）
Fig.2 NRP-1 expression was decreased in xenograft tissues after the treatment of NRP-1mAb combined with MCT therapy（×400）
A: Ctrl group; B: NRP-1mAb group; C: MCT group; D: NRP-1mAb+MCT group
图3 NRP-1mAb与MCT联合治疗后移植瘤组织中VEGF表达水平下降（×400）
Fig.3 VEGF expression was decreased in xenograft tissues after the treatment of NRP-1mAb combined with MCT therapy（×400）
A:Ctrl group; B: NRP-1mAb group; C: MCT group; D: NRP-1mAb+MCT group
图4 NRP-1mAb与MCT联合治疗后移植瘤组织中MVD表达水平下降（×400）
Fig.4 MVD expression was decreased in xenograft tissues after the treatment of NRP-1mAb combined with MCT therapy（×400）
表2 NRP-1mAb与MCT联合治疗后移植瘤组织中
MVD和VEGF表达水平下降(n=6，xˉ±s)
Tab.2 Expressions of MVD and VEGF descended after






















































































[参 考 文 献]
[1] HANAHAN D, BERGERS G, BERGSLAND E. Less is more, regu -
larly:metronomicdosing of cytotoxic drugs can target tumor angio -
genesis in mice[J]. Clin Invest, 2000, 105(8): 1045-
1047. DOI: 10.1172/JCI9872
[2] 倪二茹,曾凡伟 .抗人NRP1单克隆抗体的活性鉴定及初步应用
[J].免疫学杂志, 2012, 8(28): 651-655. DOI:10.13431/j.cnki.immu-
nol.j.20120151
[3] NAM JO, SON HN, JUN E, et al. FAS1 domain protein inhibits
VEGF165-induced ngiogenesis by targeting the interaction between
VEGF-2 and αvβ3 integrin［J］. Mol Cancer Res, 2012, 10(8): 1010-
1020. DOI: 10.1158/1541-7786.MCR-11-0600.
[4] NOWACKA M M, OBUCHOWICZ E. Vascular endothelial growth
factor (VEGF) and its role in the central nervous system: a new ele-
ment in theneurotrophic hypothesis of antidepressant drug action
[J]. Neuropeptides, 2012, 46(1): 1-10. DOI: 10. 1016/j.npep. 2011.
05.005.
[5] RAIMONDI C, FANTINA, LAMPROPOULOU A, et al. Imatinib in-
hibits VEGF-independent angiogenesis by targeting neuropilin 1-de-
pendent ABL1 activation in endothelial cells[J]. J Exp Med,
2014, 211(6): 1167-1183. DOI: 10.1084/jem.20132330.
[6] JIA H, CHENG L, TICKNER M, et al. Neuropilin-1 antagonism in
humancarcinoma cells inhibits migrationand enhances chemosensi-
tivity[J]. Br J Cancer, 2010, 102(3): 541- 552. DOI: 10.1038/sj.bjc.
6605539.
[7] 丁园,周娟,等 . NRP-1b1/b2单克隆抗体对裸鼠胃癌移植瘤生长的




(4): 252-256. DOI: 1007-3639(2009)04-0252-05.
[9] BANG Y U, VANCUTSE M E, FEYEREISLOV A A, et al. Trastu-
zumab in combination with chemotherapy versus chemotherapy
alone for treatment of HER2- positive advanced gastric or gastro-
esophageal junction cancer(ToGA): a phase 3,oen-label,randomised
controlled trial[J]. The Lancet, 2010, 376(9742): 687- 697. DOI:
10.1016/S0140-6736(10)61121-X.
[10] WADDELL T, CHAU I, CUNNINGHAM D, et al. Epirubicin,oxali-
platin,andcapecitabine with or without panitumumab for patients
with previously untreated advanced oesophagogastric cancer (RE-
AL3):a randomised,open-label phase 3 trial[J]. The Lancet Oncolo-
gy, 2013, 14(6): 481-489. DOI: 10.1016/S1470-2045(13)70096-2.
[11] OHTSU A, SHAL M A,VAN CUTSEM E, et al. Bevacizumab in
combination with chemotherapy as first- line therapy in advanced
gastric cancer:arandomized,double- blind,placebo- controlled phase
Ⅲ study[J]. J Clin Oncol, 2011(29): 3968- 3976. DOI: 10.1200/
JCO.2011.36.2236.
[12]董坚 .实体肿瘤靶向药物疗效评价标准的现状和展望[J].中国肿
瘤生物治疗杂志, 2015, 22(4): 413-419. DOI: 10.3872/j.issn.1007-
385X.2015.04.001.
[13] NADEJDA VINTONENKO, IRMA PELAEZ-GARAVITO. Overex-
pression of VEGF189 in breast cancer cells induces apoptosis via
NRP1 under stress conditions[J]. Cell Adhesion & Migration, 2011
(6): 332-343. DOI: 10.4161/cam.5.4.17287.
[收稿日期] 2017-07-11 [修回日期] 2017-11-01
[本文编辑] 韩丹
·· 1374
